COSTA MESA, Calif.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) announced that an article published yesterday by the Journal of Applied Physiology discusses research conducted with Oxycyte® in Traumatic Brain Injury (TBI) and decompression sickness. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.
